Therefore, we conducted this systematic review and meta-analysis to comprehensively assess the efficacy and safety of PI3K inhibitors combined with fulvestrant in advanced breast cancer, aiming to provide more reliable evidence-based recommendations for clinical practice. This evidence concerns the gene PIK3CA and breast carcinoma.